Jonathan Jay Mazelsky - 31 Dec 2025 Form 4 Insider Report for DENTSPLY SIRONA Inc. (XRAY)

Reporting relationship: Director
Issuer ticker: XRAY
Reported as of: 31 Dec 2025
Net transaction value: +$29,993
SEC form: 4
Accepted by SEC: 02 Jan 2026, 16:30:38 UTC
Prior SEC filing: 15 Oct 2025
Next SEC filing: 13 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Jessica Nielsen Causey, Attorney-in-Fact for Jonathan Jay Mazelsky

Key filing fact

Jonathan Jay Mazelsky filed Form 4 for DENTSPLY SIRONA Inc. (XRAY) on 02 Jan 2026.

Key facts

This page summarizes Jonathan Jay Mazelsky's Form 4 filing for DENTSPLY SIRONA Inc. (XRAY).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Jan 2026, 16:30.

Change

Previous filing in this sequence was filed on 15 Oct 2025.
Current net transaction value: +$29,993.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001556270 Primary reporting owner

MAZELSKY JONATHAN JAY

Relationship: Director
Address: C/O DENTSPLY SIRONA INC, 13320-B BALLANTYNE CORPORATE PLACE, CHARLOTTE
Signature: /s/ Jessica Nielsen Causey, Attorney-in-Fact for Jonathan Jay Mazelsky
Signature date: 02 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

XRAY transaction Derivative

Phantom Stock (Directors' Deferred Compensation) DDC

Award

Transaction value: $29,993
Shares: +2,638
Change %: +22%
Price: $11.37
Shares after: 14,382
Date: 31 Dec 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,638
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director.

Footnote F2

Comprised of phantom stock.